That's a topic a lot of people in the HIV community have strong feelings about, and understandably so. The Gilead lawsuit centers on claims that the company delayed developing a safer version of tenofovir (TAF) to protect profits from the older version (TDF), which has been linked to kidney and bone density issues.
Here's Show Full Answer
That's a topic a lot of people in the HIV community have strong feelings about, and understandably so. The Gilead lawsuit centers on claims that the company delayed developing a safer version of tenofovir (TAF) to protect profits from the older version (TDF), which has been linked to kidney and bone density issues.
Here's a quick breakdown of the two drugs at the heart of this:
- TDF (Tenofovir Disoproxil Fumarate) – found in Truvada, associated with higher risks of kidney damage and bone density loss
- TAF (Tenofovir Alafenamide) – found in Descovy, considered safer for kidneys and bones, but linked to higher cholesterol
The frustration many people feel is valid — if a safer option existed sooner, some people may have avoided those side effects.
As for the court leaning toward Gilead, legal outcomes in pharmaceutical cases can be complex and don't always reflect what's morally right. It's worth keeping an eye on updates from HIV advocacy organizations who are closely monitoring this.
Most importantly, if you're concerned about side effects from Truvada or related medications, it's worth having an open conversation with your doctor about whether switching to a newer formulation might be right for you.
July 29
Oh my. Do you have a link?
July 30
Join
Your Privacy Choices
